

REPORT FORMAT: V-L6 (Bank - P&M) | Version: 11.0_2022

CASE NO: VIS(2023-24)-PL178-152-214

DATED: 18/07/2023

VALUATION REPORT

OF

NATURE OF ASSETS	PLANT & MACHINERY AND OTHER FIXED ASSETS
CATEGORY OF ASSETS	INDUSTRIAL
TYPE OF ASSETS	INDUSTRIAL PLANT

SITUATED AT M/S. MEDISYS BIOTECH PVT. LTD., VILLAGE-MOGINAND, KALA AMB, TEHSIL-NAHAN, DISTRICT-SIRMOUR, HIMACHAL PRADESH

- Corporate Valuers
- Business/ Enterprise/ Equity Valuations
- Lender's Independent Engineers (LIE)

OWNER/S

M/S. MEDISYS BIOTECH PVT. LTD.

- REPORT PREPARED FOR
- Techno Economic Viability Copyrights (TEDANK, SAM BRANCH, SECTOR-17, CHANDIGARH
- Agency for Specialized Account Monitoring (ASM)
 - ase of any query/ is ue/ concern or escalation you may please contact Incident Manager @
- Project Techno-Financial Advisors@rkassociates.org. We will appreciate your feedback in order to improve our services.
- Chartered Engineers As per IBA Guidelines please provide your feedback on the report within 15 days of its submission after which report will be considered to be accepted & correct.
- Industry/Trade Rehabilitation Consultants & Valuer's Important Remarks are available at www.rkassociates.org for reference.
- NPA Management

CORPORATE OFFICE:

D-39, 2nd floor, Sector 2, Noida-201301 Ph - +91-0120-4110117, 4324647, +91 - 9958632707

E-mail - valuers@rkassociates.org | Website: www.rkassociates.org

Panel Valuer & Techno Economic Consultants for PSU



Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

VALUATION ASSESSMENT

M/S. MEDISYS BIOTECH PVT. LTD.



PART A

SNAPSHOT OF THE PLANT/ MACHINERY UNDER VALUATION





FILE NO.: VIS(2023-24)-PL178-152-214

Page 2 of 28



M/S. MEDISYS BIOTECH PVT. LTD.



PARTB

SUMMARY OF THE VALUATION REPORT

S.NO.	CONTENTS	DESCRIPTION			
1.	GENERAL DETAILS				
a.	Report prepared for	Bank			
b.	Name & Address of Organization	M/s. Medisys Biotech	Pvt. Ltd.	1	
C.	Work Order No. & Date	Received on phone da	ated 5-07-2023		
d.	Address at which machines are located	M/s. Medisys Biotech Tehsil-Nahan, District-			
e.	Type of the Plant/ Machinery	Small scale Manufactu	uring Unit		
f.	Nature of Industry	Pharmaceutical Indust			
g.	Type of Valuation	Industrial Plant & Mac	hinery Valuation		
h.	Report Type	Plain Asset Valuation			
i.	Date of Appointment	5 July 2023			
j.	Date of Inspection of the Property	15 July 2023			
k.	Date of Valuation	18 July 2023			
1.	Date of Valuation Report	18 July 2023			
m.	Plant Technical person name, contact number & designation assisted for	Name	Relationship with Owner	Contact Number	
	Survey	Mr. Dinesh Singh	Representative	+91 92186 05016	
n.	Purpose of the Valuation	For Distress Sale of m	ortgaged assets u	inder NPA a/c	
0.	Scope of the Assessment	Non Binding Opinion Assessment of the Pla as-is-where basis.		,	
p.	Out-of-Scope of the Assessment	Assessment of the Plant & Machineries as found on site on			

FILE NO.: VIS(2023-24)-PL178-152-214

Page **3** of **28**

echno Engl



VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.



rld's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

		D	ocuments Requested	Documents Provided	
			Total 02 documents	Total 02 documents	
			requested.	provided.	
			Detailed Fixed Asset		
~	Information provided/ available for		Register		
q.	assessment		Invoices/ Bills		
			Capacity Utilization		
			Process Flow Chart		
			Machine List	Machine List	
			Balance Sheet	FA Schedule 31-03-2022	
r.	Details of the Person providing the	Nan	ne	Mr. Nishant Shukla	
	Information	Con	tact Number	+91 88744 24038	
		Ema	ail id	-	
S.	Manner in which identification of the	√	Cross checked from t	he name of the machines	
	Assets is done			R/ Machine list name plate	
			displayed on the machine	е	
		✓	Identified by the Owner's	representative	
			Identified from the availa	able Invoices	
			Identification of the ma	achines could not be done	
			properly		
		Due to large number of in		nventory, only major machines	
			have been checked		
			From name plate display	red on the property	
			Physical inspection of the	e machines could not be done	

2.	VALUATION SUMMARY	
a.	Total Prospective Fair Market Value	Rs. 90,00,000/-
b.	Total Expected Realizable	Rs. 76,50,000/-
C.	Distress Value	Rs. 67,50,000/-

3.	ENCLOSURES	
a.	Part A	SNAPSHOT OF THE MACHINES UNDER VALUATION
b.	Part B	SUMMARY OF THE VALUATION REPORT
C.	Part C	CHARACTERISTICS DESCRIPTION OF PLANT/
		MACHINERY
d.	Part D	PROCEDURE OF VALUATION ASSESMENT
e.	Enclosure 1	Google Map
f.	Enclosure 2	Photographs
g.	Enclosure 3	Valuer's Important Remarks

FILE NO.: VIS(2023-24)-PL178-152-214

Page 4 of 28



VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.

REINFORCING YOUR BUSINESS ASSOCIATES

VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.

VALUATION CENTER OF EXCELLENCE
& RESEARCH CENTRE

PART C

CHARACTERISTICS DESCRIPTION OF PLANT/ MACHINERY

S.NO.	CONTENTS	DESCRIPTION		
1.	TECHNICAL DESCRIPTION OF THE I	PLANT/ MACHINERY		
a.	Nature of Plant & Machinery	Pharmaceutical Industry		
b.	Size of the Plant	Small scale Plant		
C.	Type of the Plant	Semi Automatic / Manual		
d.	Year of Installation/ Commissioning/ COD (Commercial Operation Date)	01-04-2006		
e.	Production Capacity	20 Cr. Tablets/Capsules per annum		
f.	Capacity at which Plant was running at the time of Survey	1.00 - 1.50 Cr. Tablets/Capsules per Annum		
g.	Number of Production Lines	NA, individual machines		
h.	Condition of machines	Average.		
i.	Status of the Plant	Fully operational		
j.	Products Manufactured in this Plant	Tablets & Capsules		
k.	Recent maintenance carried out on	Details not available		
I.	Recent upgradation, improvements if done any	None		
m.	Total Gross Block & Net Block of	Gross Block Net Block		
	Assets	As per FA Schedule dated 31-03-2022		
		Rs. 3,51,00,830/- Rs. 1,02,20,774/-		
n.	Any other Details if any	M/s Medisys Biotech Pvt. Ltd. is a manufacturer of oral medicines. The plant was physically inspected on 15-07-2023 in the presence of Mr. Dinesh Singh. As on date of site visit, the plant was operational. Capsules & Tables by Brand name of Medisys are being manufactured.		
2.	MANUFACTURING PROCESS			
	Manufacturing Process Flow Chart is no	ot shared.		
3.	TECHNOLOGY TYPE/ GENERATION ANY	USED AND TECHNOLOGICAL COLLABORATIONS IF		
a.	Technology Type/ Generation Used in this Plant	Old Generation		
b.	Technological Collaborations If Any	No		
C.	Current Technology used for this Industry in Market	Automatic Plant.		



M/S. MEDISYS BIOTECH PVT. LTD.



4.	RAW MATERIALS REQUIRED & AVAILABILITY			
	Type of Raw Material	Active Pharmaceutical Ingredient (API)		
	Availability	Easily Available		
5.	AVAILABILITY & STATUS OF UTILITIES			
	Power/ Electricity	Available		
	Water	Available		
	Road/ Transport	Available		
6.	COMMENT ON AVAILABILITY OF LA	BOUR		
	Availability	Appears to be easily & adequately available and no labour issues came to our knowledge during site inspection.		
	Factory	Approximately 30 (Including Staff and Labour)		
7.	SALES TRANSACTIONAL PROSPEC	TS OF SUCH PLANTS/ MACHINERY		
	Strategic Sale as part of the ongoing co	Control Control and Indiana Profession (Control of Control of Cont		
	Reason: This is a small scale plant and	I all are general used machines which can be used in similar		
	industry and cost of dismantling and tra	ansporation will not be very high. So, for fetching maximum		
	value is through strategic sale to the pla	yers who are already into same or similar Industry who have		
	plans for expansion or any large conglo	mefrate who plans to enter into this new Industry.		
8.	DEMAND OF SUCH PLANT & MACHI	NERY IN THE MARKET		
	Appears to be good as per general info	rmation available in public domain.		
9.	INSPECTION/ SURVEY DETAILS			
a.	Plant has been surveyed by our Engine	ering Team on 15/07/2023.		
b.		e of Owner's representative. Mr. Dinesh Singh (Employee at savailable to furnish any specific detail about the machines.		
C.	Our team examined & physically verified	d the machines from the List provided by the bank/client.		
d.	We have only verified Plant & Machiner	ies on site as per scope of work defined by the bank.		
e.	Photographs have also been taken of all the machines and its accessories installed there.			
f.	Plant was found operational and in working condition at the time of survey.			
g.	Details have been cross checked as per the machine list provided to us by the company on the site during the survey.			
h.	Condition of the machines is checked	through visual observation only. No technical/ mechanical/		
	operational testing has been carried out	to ascertain the condition and efficiency of machines.		
i.	Site survey has been carried out on the technical expediency.	basis of the physical existence of the assets rather than their		





Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

VALUATION ASSESSMENT

M/S. MEDISYS BIOTECH PVT. LTD.



PART D

PROCEDURE OF VALUATION ASSESMENT

1.		GENERAL	INFORMATION				
i.	Important Dates	Date of Appointment	Date of Inspection of the Property	Date of Valuation Assessment	Date of Valuation Report		
		5 July 2023	15 July 2023	18 July 2023	18 July 2023		
ii.	Client	M/s. Medisys Bio					
iii.	Intended User	M/s. Medisys Bio					
iv.	Intended Use	as per free mark other internal	et transaction. Thi	s report is not inte eria, and consid	end of the property ended to cover any derations of any		
V.	Purpose of Valuation	For Distress Sal	e of mortgaged as	sets under NPA	a/c		
vi.	Scope of the Assessment	Non binding opinion on the assessment of Plain Physical Asset Valuation of the property identified to us by the owner or through his representative.					
vii.	Restrictions	This report should not be referred for any other purpose, by any other user and for any other date other then as specified above.					
viii.	Manner in which identification of the Assets is done	Cross checked from the name of the machines mentioned in the FAR/ Inventory list name plate displayed on the machine					
		•	by the Owner's re	·			
			from the available				
			tion of the machin				
		☐ Due to large number of machines/ inventories, only major production lines & machines have been checked					
		☐ Enquired	☐ Enquired from local residents/ public				
		☐ Physical	☐ Physical inspection of the machines could not be done				
		☐ From nar	☐ From name pate displayed on the property.				
ix.	Type of Survey conducted	Full survey (inside-out for verification of assets with photographs)					

2.	ASSESSMENT FACTORS					
i.	Valuation Standards considered	Mix of standards such as IVS and others issued by Indian authorities & institutions and improvised by the RKA internal research team as and where it is felt necessary to derive at a reasonable, logical & scientific approach. In this regard proper basis, approach, working, definitions considered is defined below which may have certain departures to IVS.				
ii.	Nature of the Valuation	Fixed Assets Valuation	n			
iii.	Natural Catagory Type	Nature	Category	Туре		
	Nature/ Category/ Type/ Classification of Asset under Valuation	PLANT & MACHINERY	INDUSTRIAL	INDUSTRIAL PLANT		
	Valuation	Classification	Income/ Revenue Ge	enerating Asset ngineen		

FILE NO.: VIS(2023-24)-PL178-152-214

ar

Page 7 of 28



VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.

ASSOCIATES VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.

VALUATION CENTER OF EXCELLENCE & RESEARCH CENTRE

World's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

iv.	Type of Valuation (Basis of	Primary Basis	Fair Market V	'alue		
	Valuation as per IVS)	Secondary Basis	On-going con	cern basis		
V.	Present market state of the	Under Normal Ma	arketable State			
	Asset assumed (Premise of Value as per IVS)	Reason: Asset under free market transaction state				
vi.	Physical Infrastructure availability factors of the locality	Water Supply	Sewerage/ sanitation system	Electricity	Road and Public Transport connectivity	
		Yes	Underground	Yes	Easily available	
		Availability of	f other public	Avai	lability of	
		utilities	nearby	communic	cation facilities	
			t, Hospital etc. are close vicinity	Service F	communication Provider & ISP as are available	
vii.	Neighbourhood amenities	Good				
viii.	Any New Development in surrounding area	None		None		
ix.	Any specific advantage/ drawback in the plant and machines	Adequate labours available in the locality				
Χ.	Machines overall usability/ utility Factor	Normal				
xi.	Subject Industrial sector/ product manufactured outlook	Fair				
xii.	Best Sale procedure to	Fair Market Value				
	realize maximum Value (in respect to Present market state or premise of the Asset as per point (iv) above)		saction at arm's leng ch acted knowledge			
xiii.	Hypothetical Sale transaction	Fair Market Value		A CAN BERNELLOS		
	method assumed for the computation of valuation		saction at arm's leng ch acted knowledge		• • • • • • • • • • • • • • • • • • • •	
xiv.	Approach & Method of	Approach	of Valuation	Method	of Valuation	
	Valuation Used	Market Approach	& Cost Approach	Method 8	mparable Sales & Depreciated ent Cost Method	
XV.	Type of Source of Information	Level 3 Input (Tertiary)				
xvi.	Any other aspect which has relevance on the value or marketability of the machines	The marketability for the machines depends upon the industry outlook make, market condition, raw material, maintenance, raw material usability, capacity. This Valuation report is prepared based on the facts of the assets 8 market situation on the date of the survey. It is a well-known fact that				

FILE NO.: VIS(2023-24)-PL178-152-214

Page **8** of **28**



M/S. MEDISYS BIOTECH PVT. LTD.



ld's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

> the market value of any asset varies with time & socio-economic conditions prevailing in the region/ country. In future assets market may go down, asset conditions may change or may go worse, plant vicinity conditions may go down or become worse, plant sector outlook may change due to impact of Govt. policies or effect of domestic/ world economy, usability prospects of the Plant may change, etc. Hence user of this report should take into consideration all such future risk while taking any business decision.

XVII. Basis of computation & working

XVIII. Main Basis:

- a. Basic Methodology: For arriving at fair market value of machines, our engineering team has applied "Market Approach (Market Comparable Sales Method" & 'Cost Approach (Depreciated Replacement Cost Method)'. The fair market value of machines on the date of valuation is its cost of reproduction depending upon their Technical, Economic, Functional specifications.
- b. Machine Valuation is done keeping in mind various factors like technology used, machines availability, its condition, average age, maintenance & service and parts replacement availability of the machines and more importantly demand in the market.
- c. No capitalization cost or purchase cost of machines were made available to us and this Valuation is done purely by gathering Project establishment capital cost for such kind of Projects on public domain or consultants working in this line.
- d. Replacement cost has been taken based on the independent market research from public domain or used machinery dealers or Project consultants.
- e. No further obsolescence/ deterioration or maintenance factor has been applied on the Depreciated Replacement Cost (DRC) since the Depreciated Replacement Cost (DRC) looks to be in line with the estimated Prospective Fair Market Value.
- f. Underline assumption for the evaluation of these machines is that it will be sold as an Integrated Plant and not as discrete/ piecemeal machinery basis.
- g. Market & Industry scenario is also explored for demand of such Plants and it is found that many other Pharma plant are also present in different states of the India.
- h. Valuation of the asset is done as found on as per the details provided to us on the site, as identified to us by owner representative during site inspection by our engineer/s unless otherwise mentioned in the report.
- The valuation of the Plant/ Machinery has been done considering the plant as a whole. The individual value for machines shown is for illustration purpose,
- Valuation of the machine is done taking into consideration that whether it is specific purpose machines or general used machines.
- k. Consolidated valuation sheet of machines and other asset items are mentioned below with depreciated current market value as per different category of the machines/assets cumulated together. Our engineering team has separated the Cost of Equipment's in the different sections of the plant. The cost of equipment considered from P&M List includes Pre-operative, Finance, and IDC Charges etc. The capitalized/ purchase cost of machinery considered from P&M List consists of final commissioning of machines which includes freight, taxes, insurance, etc.

Other Basis:

Analysis and conclusions adopted in the report are limited to the reported assumptions, conditions and information came to our knowledge during the course of the work and based on the Standard Operating Procedures, Best Practices, Caveats, Limitations, Conditions, Remarks, Important

Page 9 of 28



M/S. MEDISYS BIOTECH PVT. LTD.



Vorld's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

Notes, Valuation TOR and definition of different nature of values.

- m. The indicative value has been suggested based on the prevailing market rates that came to our knowledge during secondary & tertiary market research and is not split into formal & informal payment arrangements. Most of the deals takes place which includes both formal & informal payment components. Deals which takes place in complete formal payment component may realize relatively less actual transaction value due to inherent added tax, stamp registration liabilities on the buyer.
- n. Secondary/ Tertiary costs related to asset transaction like Installation, maintenance and Logistics costs pertaining to the sale/ purchase of the assets are not considered separately while assessing the indicative estimated Market Value and is assumed to be included in the Cost of capitalization provided by the client.
- o. The condition assessment and the estimation of the residual economic life of the machinery and assets are only based on the visual observations and appearance found during the site survey. We have not carried out any physical tests to assess the working and efficiency of the machines and assets.
- p. Any kind of unpaid statutory, utilities, lease, interest or any other pecuniary dues on the asset or on its owners has not been factored in the Valuation.
- q. Valuation is done for the asset found on as-is-where basis which owner/ owner representative/ client/ bank has shown to us on site of which some reference has been taken from the information/ data given in the copy of documents provided to us which have been relied upon in good faith and we have assumed that it to be true and correct.

xix. ASSUMPTIONS

- a. Information/ Data provided by the client/ property owner or his representative both written & verbally is true and correct without any fabrication and has been relied upon in good faith.
- b. We have not been provided maintenance record and capacity utilization of the plant. As the plant was operational and all the machines were is fair condition. Thus, it is assumed that the overall condition of the plant is fair.
- c. Market rates for each machine are not available in public domain. Thus, cost approach is applied for the valuation of machines.
- d. The assets and interests therein have been valued free and clear of any liens or encumbrances unless stated otherwise. No hidden or apparent conditions regarding the subject assets or their ownership are assumed to exist. No opinion of title is rendered in this report and a good title is assumed unless stated otherwise.
- e. It is assumed that the concerned Lender/ Financial Institution has asked for the valuation of that property after satisfying the authenticity of the documents given to us and for which the legal verification has been already taken and cleared by the competent Advocate before requesting for the Valuation report. I/ We assume no responsibility for the legal matters including, but not limited to, legal or title concerns.
- f. Payment condition during transaction in the Valuation has been considered on all cash basis which includes both formal & informal payment components as per market trend.
- g. Sale transaction method of the asset is assumed as Free market transaction without any compulsion unless otherwise mentioned while assessing Indicative & Estimated Fair Prospective Market Value of the asset unless otherwise stated.

XX. SPECIAL ASSUMPTIONS

Copy of latest available FAR is not shared with us. Thus, we have relied upon machine list shared with us for valuation purpose.

xxi. LIMITATIONS

No

FILE NO.: VIS(2023-24)-PL178-152-214

Page **10** of **28**



www.valuationintelligentsystem.com

VALUATION ASSESSMENT

REINFORCING YOUR BUSINESS _ ASSOCIATES VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD. VALUATION CENTER OF EXCELLENCE

M/S. MEDISYS BIOTECH PVT. LTD.

SUMMARY OF PLANT & MACHINERY M/S. MEDISYS BIOTECH PVT. LTD., VILLAGE-MOGINAND, KALA AMB, TEHSIL-NAHAN, DISTRICT-SIRMOUR, HIMACHAL PRADESH

S. No.	Particulars	Net Book Value	Estimated Reproduction Cost of the Asset	Fair Market Value
1	Production Equipment		₹ 1,71,07,268	₹ 60,10,710
2	Quality Equipment	₹ 1,02,20,774	₹ 29,31,325	₹ 6,49,655
3	Ancillary Equipment		₹ 61,56,402	₹ 23,22,810
	Total	₹ 1,02,20,774	₹ 2,61,94,995	₹ 89,83,175

- 1. Assets items pertaining to M/S. Medisys Biotech Pvt. Ltd., are located at Village-Moginand, Kala Amb, Tehsil-Nahan, District-Sirmour, Himachal Pradesh.
- 2. We have been provided FA schedule dated 31-03-2022 & list of machines related to production & quality installed in the plant. Copy of FAR is not shared with us.
- 3. Details of ancillary equipment such RO plant, ETP, Compressor, DG Set, Transformer are considered from Old valuation report shared & physically inspected on site. As mentioned in Old Valuation Report, AHU, Electrical fittings & miscellaneous assets, are not considered in the valuation as specific details/ capitalized amount is not shared with us.
- 4. As per information received during site survey, the plant was commissioned in the year 2006 and capitalization year of each machine/equipment is not available with us. Thus, we have considered balance economic life of each machine 3-8 years depending upon their usage. Since the plant is operational and condition of machines are average.
- 5. For evaluating the Gross reproduction cost of the machines and equipment's, we have adopted the Sales Comparable Method (Market Approach). Further, we depreciated each machines based upon its usage/condition.
- We have verified the machines mentioned in Machine List to us by the bank/client.

As on date of site visit, the plant was operational.

chno Eng



VALUATION ASSESSMENT M/s. MEDISYS BIOTECH PVT. LTD.



World's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

3.	CONSOLIDATED VALUATION ASSESSMENT OF THE PLANT AND MACHINERY						
S. No.	Particulars	Book Value	Indicative & Estimated Prospective Fair Market Value				
a.	Plant & Machinery Value	Rs. 1,02,20,774/-	Rs. 89,83,175/-				
b.	Additional Premium if any						
	Details/ Justification						
C.	Deductions charged if any						
0.	Details/ Justification						
d.	Total Indicative & Estimated		Do 90 92 475/				
u.	Prospective Fair Market Value		Rs. 89,83,175/-				
e.	Rounded Off		Rs. 90,00,000/-				
	Indicative & Estimated Prospective						
f.	Fair Market Value in words	Rupees Nin	ety Lakhs Only				
	Expected Realizable Value (@ ~15%						
g.	less)	·	Rs. 76,50,000/-				
	Expected Distress Sale Value (@		D 07 50 000/				
h.	~25% less)		Rs. 67,50,000/-				
i.	Concluding Comments/ Disclosures if	any					
	 a. We are independent of client/ company and do not have any direct/ indirect interest in the property. b. This valuation has been conducted by R.K Associates Valuers & Techno Engineering Consultants (P) Ltd. and its team of experts. c. This Valuation is done for the property found on as-is-where basis as shown on the site by the Bank/ customer of which photographs is also attached with the report. d. Reference of the property is also taken from the copies of the documents/ information which interested organization or customer could provide to us out of the standard checklist of documents sought from them and further based on our assumptions and limiting conditions. All such information provided to us has been relied upon in good faith and we have assumed that it is true and correct. However we do not vouch the absolute correctness of the property identification, exact address, physical conditions, etc. based on the documents provided to us since property shown to us may differ on site Vs as mentioned in the documents or incorrect/ fabricated documents may have been provided to us. e. Legal aspects for eg. investigation of title, ownership rights, lien, charge, mortgage, lease, verification of documents from originals or from any Govt. department, etc. has to be taken care by legal experts/ Advocates and same has not been done at our end. f. The valuation of an asset is an estimate of the worth of that asset which is arrived at by the Valuer in his expert opinion after factoring in multiple parameters and externalities. This may not be the actual price of that asset and the market may discover a different price for that asset. 						
	g. This report only contains opinion based on technical & market information which came to our knowledge during the course of the assignment. It doesn't contain any recommendations.						

FILE NO.: VIS(2023-24)-PL178-152-214

Page 12 of 28



WALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.

REINFORCING YOUR BUSINESS®

ASSOCIATES

VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.

VALUATION CENTER OF EXCELLENCE

nld's first fully digital Automated Platform fo. Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

- h. This report is prepared following our Standard Operating Procedures & Best Practices and will be subject to Limitations, Conditions, Valuer's Remarks, Important Notes, Valuation TOS and basis of computation & working as described above.
- i. The use of this report will become valid only after payment of full fees as per the Payment Terms. Using this report or any part content created in this report without payment of charges will be seen as misuse and unauthorized use of the report.

j. IMPORTANT KEY DEFINITIONS

Fair Value suggested by the competent Valuer is that prospective estimated amount in his expert & prudent opinion of the subject asset/ property without any prejudice after he has carefully & exhaustively evaluated the facts & information came in front of him or which he could reasonably collect during the course of the assessment related to the subject asset on an as-is, where-is basis in its existing conditions, with all its existing advantages & disadvantages and its potential possibilities which is just & equitable at which the subject asset/ property should be exchanged between a willing buyer and willing seller at an arm's length transaction in an open & unrestricted market, in an orderly transaction after proper marketing, wherein the parties, each acted knowledgeably, prudently without any compulsion on the date of the Valuation.

Fair Value without using the term "Market" in it describes that the value suggested by the Valuer may not mandatorily follow or may not be in complete consonance to the established Market in his expert opinion. It may or may not follow market dynamics. But if the suggested value by the valuer is not within the prevailing Market range or is assessed for an asset is located in an un-established Market then the valuer will give reasonable justification & reasoning that for what reasons the value suggested by him doesn't follow the prevailing market dynamics.

Fair Market Value suggested by the competent Valuer is that prospective estimated amount in his expert & prudent opinion of the subject asset/ property without any prejudice in consonance to the Market dynamics after he has carefully & exhaustively evaluated the facts & information came in front of him or which he could reasonably collect during the course of assessment related to the subject asset on an asis, where-is basis in its existing conditions, with all its existing advantages & disadvantages and its potential possibilities which is just & equitable at which the subject asset/ property should be exchanged between a willing buyer and willing seller at an arm's length transaction in an open & unrestricted market, in an orderly transaction after proper marketing, wherein the parties, each acted knowledgeably, prudently without any compulsion on the date of the Valuation.

Here the words "in consonance to the established Market" means that the Valuer will give opinion within the realms & dynamics of the prevailing market rates after exhaustively doing the micro market research. However due to the element of "Fair" in it, valuer will always look for the factors if the value should be better than the market realms which is just & equitable backed by strong justification and reasoning.

Market Value suggested by the competent Valuer is that prospective estimated amount which is average price of the similar comparable assets prevailing in an open & established market during the near period of the date of valuation at which the subject asset/ property should be exchanged between a willing buyer and willing seller on an as-is, where-is basis in its existing conditions, with all its existing advantages & disadvantages and its potential possibilities at an arm's length transaction in an open, established & unrestricted market, in an orderly transaction, wherein the parties, each acted without any compulsion on the date of the Valuation.

Using the term "Market Value" without "Fair" omits the elements of proper marketing, acting knowledgeably & prudently.

Market and market participants can be sentimental, inclined towards the transaction without the element of complete knowledge & prudence about facts or due diligence of the asset therefore "each acted

FILE NO.: VIS(2023-24)-PL178-152-214

Page 13 of 28



www.valuationintelligentsystem.com

WALUATION ASSESSMENT M/S, MEDISYS BIOTECH PVT, LTD.



knowledgeably, prudently" has been removed from the marker Value definition.

Realizable Value is that minimum prospective estimated value of the asset/ property which it may be able to fetch at the time of actual property transaction factoring in the element of discount due to the prospects of deep negotiations between the buyer & seller when the parties in-principally find Fair Market Value reasonable and sits together to close the deal and the transaction across the table. Discount percentage on the Fair Market Value due to negotiation will depend on the nature, size, various salability prospects of the subject asset, the needs of the buyer & the seller and kind of payment terms. In some of the cases Realizable and Fair Market Value may also be equal.

Distress Sale Value* is that value when the property is attached with any process such as mortgaged financing, financial or operational dues which is under any stress condition or situation and the stakeholders are under process of finding resolution towards it to save the property from being attached to a formal recovery process. In this type of sale, minimum fetch value assessed will always be less than the estimated Fair Market Value where the discount of percentage will depend upon various circumstances and factors such as nature, size, salability prospects of the property and kind of encumbrance on the property. In this type of sale, negotiation power of the buyer is always more than the seller and eagerness & pressure of selling the property will be more on the seller than the buyer.

Liquidation Value is the amount that would be realized when an asset or group of assets are sold due to any compulsion or constraints such as in a recovery process guided by statute, law or legal process, clearance sale or any such condition or situation thereof where the pressure of selling the asset/ property is very high to realize whatever maximum amount can be from the sale of the assets in a limited time for clearance of dues or due to closure of business. In other words, this kind of value is also called as forced sale value.

Difference between Cost, Price & Value: Generally, these words are used and understood synonymously. However, in reality each of these has a completely different meaning, premise and also having different definitions in professional & legal terms. Therefore, it is our professional responsibility to describe the definitions of these words to avoid ambiguity & confusion in the minds of the user of this report.

The **Cost** of an asset represents the actual amount spend in the construction/ actual creation of the asset.

The **Price** is the amount paid for the procurement of the same asset.

The **Value** is defined as the present worth of future rights in the property/ asset and is a hypothetical or notional price that buyers and sellers are most likely to conclude for a good or service. Value is not a fact, but an estimate of the likely price to be paid for a good or service at a given time in accordance with a particular definition of value.

Therefore, in actual for the same asset/ property, cost, price & value remain different since these terms have different usage & meaning.

k. Enclosures with the Report:

- Enclosure: I Google Map Location
- Enclosure: II Photographs of the property
- Enclosure III Valuer's Important Remarks

bli





VALUATION ASSESSMENT M/s. MEDISYS BIOTECH PVT. LTD.

REINFORCING YOUR BUSINESS®

ASSOCIATES

VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.

VALUATION CENTER OF EXCELLENCE

Integrating Valuation Life Cycle A product of R.K. Associates
www.valuationintelligentsystem.com

IMPORTANT NOTES

<u>DEFECT LIABILITY PERIOD</u> - In case of any query/ issue or escalation you may please contact Incident Manager by writing at valuers@rkassociates.org. We try our level best to ensure maximum accuracy in the Calculations done, Rates adopted and various other data points & information mentioned in the report but still can't rule out typing, human errors, assessment or any other mistakes. In case you find any mistake, variation, discrepancy or inaccuracy in any data point mentioned in the report, please help us by bringing all such points into our notice in writing at valuers@rkassociates.org within 30 days of the report delivery, to get these rectified timely, failing which R.K Associates shouldn't be held responsible for any inaccuracy in any manner. Also, if we do not hear back anything from you within 30 days, we will assume that the report is correct in all respect and no further claim of any sort will be entertained thereafter. We would welcome and appreciate your feedback & suggestions in order to improve our services.

Our **DATA RETENTION POLICY** is of **ONE YEAR**. After this period we remove all the concerned records related to the assignment from our repository. No clarification or query can be answered after this period due to unavailability of the data.


<u>COPYRIGHT FORMAT</u> - This report is prepared on the copyright format of R.K Associates to serve our clients in the best possible way. Legally no one can copy or distribute this format without prior approval from R.K Associates. It is meant only for the organization as mentioned on the cover page of this report. Distribution or use of this format or any content of this report wholly or partially other than R.K Associates will be seen as unlawful act and necessary legal action can be taken against the defaulters.

NOTE: As per IBA Guidelines in case the valuation report submitted by the valuer is not in order, the banks / FIs shall bring the same to the notice of the valuer within 15 days of submission for rectification and resubmission. In case no such communication is received, it shall be presumed that the valuation report has been accepted.

At our end we have not verified the authenticity of any documents provided to us. Bank is advised to verify the genuineness of the property documents before taking any credit decision.

Valuation Terms of Services & Valuer's Important Remarks are available at www.rkassociates.org for reference.

SURVEY ANALYST	VALUATION ENGINEER	L1/ L2 REVIEWER
Manas Upmanyu	Abhinav Chaturvedi	Manas Upmanyu
M	lati-	M






FILE NO.: VIS(2023-24)-PL178-152-214 Page 15 of 28




Integrating Valuation Life Cycle www.valuationintelligentsystem.com VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.



ENCLOSURE: 1- GOOGLE MAP LOCATION







Page 16 of 28




Integrating Valuation Life Cycle A product of R.K. Associates
www.valuationintelligentsystem.com


VALUATION ASSESSMENT


M/S. MEDISYS BIOTECH PVT. LTD.




ENCLOSURE: 1- PHOTOGRAPHS









FILE NO.: VIS(2023-24)-PL178-152-214


Page **17** of **28**




M/S. MEDISYS BIOTECH PVT. LTD.




World's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

















M/S. MEDISYS BIOTECH PVT. LTD.




s first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

















VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.


REINFORCING YOUR BUSINESS[®]
ASSOCIATES
VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.
WALUARDON CENTER OF EXCELLENCE

World's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com













VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.

REINFORCING YOUR BUSINESS ASSOCIATES VALUATION CENTER OF EXCELLENCE & RESEARCH CENTRE

ld's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com













Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

VALUATION ASSESSMENT

M/S. MEDISYS BIOTECH PVT. LTD.



ENCLOSURE: 2- IMPORTANT PROPERTY DOCUMENTS EXHIBIT

FA Schedule- 31-03-2022

						Contract of States and Contract of States						
MEDISTS BIOTECH PRIVATE LIMITED												
Notes to Provisional Financial Scatements for the Year Ended Mar Note 11: Property Plant & Equipment	vh 31, 2022											(Amt in 100)
Property Plant & Equipment	Property Plant & Equipment Gross Block					A	ccumulated De	preciation			Net Block	
	Balance as at April 1, 2021	Additions	Otsposals	Balance 96 at March 31, 2022	Belance at at March 33, 2023	Depreciation charge for the year	Adjustment due to revaluations	On disposals	Transferred to RSS	Balance as at March 31, 2022	Balance as at March 31, 2022	Balance as at March X1, 2021
A. Tarqhie Assets							7 - DV - 12					The state of the s
Land	18,299.80			18,299.80							16,299.80	18,399.80
Building	2,45,157.65			2,45,157.65	1,72,648.69	6,821.27	- 102		1	1,29,968,97	1,16,187,68	1,27,506.90
Plant & Machinery	1,46,227.52	2,780.76	-	3,51,008.30	2,26,614.98	22,185.58				2,48,600.56	1,02,207.74	1,71,612.54
Office Equipment	18530.69	1000000		13,530,69	11,821.65	134.67		20		11,958.32	1,572.37	1,707.0
Furniture & Fictures	16,716.58			16,736.58	14,300.00	349.55	year and	2 2		14,649.55	7,087.03	2,496.50
Computers	26,007,69	110.17		28,117.86	26,105.06	364.31	- 6	0 01	1	26,469.39	1,648.47	1,902.6
Electrical installations	E1,060.69	171.12		81,251.81	65,419.83	875.89		10 47		66,295.72	14,936.09	15,640.8
Vahiklis	12,464.91			12,464.91	7,057,72	720.57	-	100		7,778.29	4,686.62	5,407.35
Total	7,63,465.53	1,062.07		7,66,547.60	4,71,969.96	30,951.84				5,64,921.80	2,61,625.80	2,89,515.5
6. Intangible Assets	THE PROPERTY OF	7 7 7 7	0.00					3			1000	
Technical Knowhow	1,45,276.13	1		1,45,726.33	1,45,192.87				13 13	1,45,192.82	33.26	31.2
Product Development expenditure	38,867.06		100	58,867,06	15,455.13	4,102.63		-		29.557.26	15,509.50	19,411.9
Total	1,84,093.19	100		1,84,093.19	1,64,648.00	4,102.63		200		1,68,750.63	15,342.56	19,445.1
Yotal as at March \$1, 2022	9,47,578.72	3,062.07	- 41	9,50,640.79	6,38,617.95	35,054.46				6,71,672.43	2,76,968.36	3,08,960.7
Previous Year as at March 31, 2011	9,45,006.22	2,572.50	No.	9,47,578.72	6,03,776.22	\$4,843.75	50.72		- 20	638,617.95	3,08,960,77	3,41,230.0





M/S. MEDISYS BIOTECH PVT. LTD.



LIST OF EQUIPMENT IN PRODUCTION

Name of machine	Number Of Machine	Capacity
Coating pan	M/PR/E001	48 inch
Fluid Bed Coater	M/PR/E002	45 kg
Fluid Bed Coater	M/PR/E003	60 kg
Fluid Bed Coater	M/PR/E004	90 kg
Coating pan	M/PR/E005	14 inch
Coating pan	M/PR/E006	36 inch
Coating pan	M/PR/E007	48 inch
Coating pan	M/PR/E008	48 inch
Single rotary Tableting machine "D" Tooling GMP Model DPMD3-16"	M/PR/E009	16 station
Double Rotary Tableting machine "D" tooling GMP Model "DPMD3B-27"	M/PR/E010	27 station
Mix-well hot air 48 Tray dryer GMP model	M/PR/E011	
Mix-well hot air 48 Tray dryer GMP model	M/PR/E012	
Mix-well hot air 24 Tray dryer GMP model	M/PR/E013	
Mix-well hot air 48 Tray dryer GMP model	M/PR/E014	
Mix-well Double cone blender Capacity 300 ltrs. O.F.C. GMP	M/PR/E015	300 Ltrs
Mix-well Double cone blender Capacity 500 ltrs. O.F.C. GMP	M/PR/E016	500 Ltrs
Mix-Well Shifter Machine Size 30" Dia GMP model	M/PR/E017	30 inch
Mix-Well Shifter Machine Size 30" Dia GMP model	M/PR/E018	30 inch
Mix-Well Shifter Machine Size 30" Dia GMP model	M/PR/E019	30 Inch
PRISM TM Fluid Bed Dryer Model Batch Size 60 kg	M/PR/E020	120 Ltrs
PRISM TM RMG 150 liters/60 Kg	M/PR/E021	150 ltrs
PRISM TM COLLOID MILL GMP MODEL	M/PR/E022	
PRISM TM MULTI MILL GMP MODEL	M/PR/E023	
PRISM TM VIBROSIFTER 30" GMP MODEL	M/PR/E024	30 inch
Pam Pac machine BP-102	M/PR/E025	
Pam SA 9 machine with deduster	M/PR/E026	
Polishing machine	M/PR/E027	
Extruder	M/PR/E028	
Spherunizer	M/PR/E029	
Stirrer	M/PR/E030	
Stirrer	M/PR/E031	
PORTABLE Vaccum Cleaner	M/PR/E032	
PORTABLE DEHUMIDIFIER	M/PR/E033	
PORTABLE DEHUMIDIFIER	M/PR/E034	
Coating Pan	M/PR/E035	48 inch
Pulverizer	M/PR/E036	
Fluid Bed Coater	M/PR/E037	250 kg
Batch Number printing Machine	M/PR/E062	
Alu-Alu- Packing Machine	M/PR/E063	
Fluid Bed Coater (300 Kg)	M/PR/E065	
Hot Air Tray dryer	M/PR/E073	48 tray
Shifter Machine	M/PR/E074	30 inch



M/S. MEDISYS BIOTECH PVT. LTD.



Master List of Equipment/Instrument Codes

ID NUMBER	EQUIPMENT/ INSTRUMENT NAME	MAKE	LOCATION
MB/QC/004	Electronic Balance	Shimadzu	Instrumentation area 1st
MB/QC/007	Polarimeter	Multitech Instrument	Chemical testing Lab
MB/QC/008	Hot air Oven	Multitech Instrument	Hot zone area
MB/QC/009	Hot air Oven	Multitech Instrument	Hot zone area
MB/QC/010	Disintegration Test Apparatus	Veego	IPQC
MB/QC/011	Magnetic Stirer with Hot Plate	Multitech Instrument	Chemical testing Lab
MB/QC/012	Magnetic Stirer with Hot Plate	Multitech Instrument	Chemical testing Lab
MB/QC/013	Muffle Furnance	Multitech Instrument	Out of Service
MB/QC/014	Water Bath	Multitech Instrument	Chemical testing Lab
MB/QC/016	Melting Point Apparatus	Veego	Chemical testing Lab
MB/QC/017	Tap Density Apparatus	Veego	Chemical testing Lab
MB/QC/018	Laminar Air Flow	Multitech Instrument	Micro lab
MB/QC/019	Vertical Autoclave	Multitech Instrument	Micro lab
MB/QC/020	Bacteriological Incubator	Multitech Instrument	Micro lab
MB/QC/021	BOD Incubator	Multitech Instrument	Micro lab
MB/QC/022	Colony Counter	Multitech Instrument	Micro lab
MB/QC/023	Microscope	MetzerOpticals	Micro lab
MB/QC/024	Leak Test Apparatus	Multitech Instrument	IPQC
MB/QC/025	Vaccum Oven	Multitech Instrument	Hot Zone area
MB/QC/026	Friability Test Apparatus	Veego	IPQC
MB/QC/027	Disintegration Test Apparatus	Multitech Instrument	IPQC
MB/QC/030	Micro pipette 100-1000µl	Loba life	Micro
MB/QC/031	Micro pipette 10-100µl	Riviera+	Micro
MB/QC/032	Balance	Shimadzu	IPQC
MB/QC/035	Hardness Tester	Veego	IPQC
MB/QC/037	Balance	Dhona	Micro lab
MB/QC/038	Friability test Apparatus	Multitech Instrument	IPQC
MB/QC/039	Stability Chamber	Multitech Instrument	MICRO
MB/QC/040	Stability Chamber	Multitech Instrument	Micro Lab
MB/QC/046	Refrigerator	LG	Micro
MB/QC/048	Karl fischerTitrator	Lab India	Instrumentation area 1st
MB/QC/052	High Performance Liquid Chromatography	Agilent Technologies	Instrumentation area 2 nd
MB/QC/053	Dissolution Test Apparatus	Lab India	Instrumentation area 1st
MB/QC/058	Muffle Furnance	VL Scientific	Hot zone QC
MB/QC/059	Humidity meter	Acurite	
MB/QC/123	Sonicator	Sarthak	Chemical testing lab
MB/QC/130	TACHOMETER	KUSAM-MECO	Instrumentation room
MB/QC/131	Oven	VL Scientific	Micro Lab
MB/QC/138	pH meter	SARTHAK	QC
MB/QC/142	Spectrophotometer (UV / VISIBLE)	Shimadzu	Instrumentation area 2 ^{nc}
MB/QC/153	Dissolution Apparatus	Lab India	Instrumentation area 1st
MB/QC/159	Conductivity Meter	Globe Instrument	Chemical testing lab
MB/QC/160	Shimadzu Balance Model No. BL 220H Sr. No. D432913333	Shimadzu	Chemical testing lab



VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.



World's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

ENCLOSURE: 3 – VALUER'S IMPORTANT REMARKS

1.	Valuation is done for the asset found on as-is-where basis which owner/ owner representative/ client/ bank has shown/ identified to us on the site unless otherwise mentioned in the report of which some reference has been taken from the information/ data given in the copy of documents provided to us and informed verbally or in writing out of the standard checklist of documents sought from the client & its customer which they could provide within the reasonable expected time out of the standard checklist of documents sought from them and further based on certain assumptions and limiting conditions. The information, facts, documents, data which has become primary basis of the report has been supplied by the client which has been relied upon in good faith and is not generated by the Valuer.
2.	The client/ owner and its management/ representatives warranted to us that the information they have supplied was complete, accurate and true and correct to the best of their knowledge. All such information provided to us either verbally, in writing or through documents has been relied upon in good faith and we have assumed that it is true & correct without any fabrication or misrepresentation. I/We shall not be held liable for any loss, damages, cost or expenses arising from fraudulent acts, misrepresentations, or willful default on part of the owner, company, its directors, employee, representative or agents.
3.	Legal aspects for eg. Investigation of title, ownership rights, lien, charge, mortgage, lease, sanctioned maps, verification of documents provided to us such as title documents, Map, etc. from any concerned Govt. office etc. have to be taken care by legal expert/ Advocate and same is not done at our end. It is assumed that the concerned Lender/ Financial Institution has asked for the valuation of that property after satisfying the authenticity of the documents given to us for which the legal verification has been already taken and cleared by the competent Advocate before requesting for the Valuation report. I/ We assume no responsibility for the legal matters including, but not limited to, legal or title concerns.
4.	In the course of the valuation, we were provided with both written and verbal information. We have however, evaluated the information provided to us through broad inquiry, analysis and review but have not carried out a due diligence or audit of the information provided for the purpose of this engagement. Our conclusions are based on the assumptions and other information provided to us by the client during the course of the assessment.
5.	Getting cizra map or coordination with revenue officers for site identification is a separate activity and is not part of the Valuation services and same has not been done in this report unless otherwise stated.
6.	Wherever any details are mentioned in the report in relation to any legal aspect of the property such as name of the owner, leases, etc. is only for illustration purpose and should not be construed as a professional opinion. Legal aspects are out of scope of this report. Details mentioned related to legal aspect are only based on the copy of the documents provided to us and whatever we can interpret as a non-legally trained person. This should be cross validated with a legal expert. We do not vouch any responsibility regarding the same.
7.	We have made certain assumptions in relation to facts, conditions & situations affecting the subject of, or approach to this exercise that has not been verified as part of the engagement rather, treated as "a supposition taken to be true". If any of these assumptions prove to be incorrect then our estimate on value will need to be reviewed.
8.	This is just an opinion report based on technical & market information having general assessment & opinion on the indicative, estimated Market Value of the property for which Bank has asked to conduct the Valuation. It doesn't contain any other recommendations of any sort including but not limited to express of any opinion on the suitability or otherwise of entering into any transaction with the borrower.
9.	We have relied on the data from third party, external sources & information available on public domain to conclude the valuation. These sources are believed to be reliable and therefore, we assume no liability for the truth or accuracy of any data, opinions or estimates furnished by others that have been used in this analysis. Where we have relied on the data, opinions or estimates from external sources, reasonable care has been taken to ensure that such data is extracted from authentic sources, however we still can't vouch its authenticity, correctness, or accuracy.
10.	Analysis and conclusions adopted in the report are limited to the reported assumptions, conditions and information came to our knowledge during the course of the work and based on the Standard Operating Procedures, Best Practices, Caveats, Limitations, Conditions, Remarks, Important Notes, Valuation TOR and definition of different nature of values.
11.	Value varies with the Purpose/ Date/ Asset Condition & situation/ Market condition, demand & supply, asset utility prevailing on a particular date/ Mode of sale. The indicative & estimated prospective Value of the asset given in this report is restricted only for the purpose and other points mentioned above prevailing on a particular date as mentioned in the report. If any of these points are different from the one mentioned aforesaid in the Report then this report should not be referred.
12.	Our report is meant ONLY for the purpose mentioned in the report and should not be used for any other purpose. The Report should not be copied or reproduced for any purpose other than the purpose for which it is prepared for. I/we do not take any responsibility for the unauthorized use of this report.
13.	We owe responsibility only to the authority/client that has appointed us as per the scope of work mentioned in the report. We will not be liable for any losses, claims, damages or liabilities arising out of the actions taken, omissions or advice given by any other person. In no event shall we be liable for any loss, damages, cost or expenses arising
	1.27

FILE NO.: VIS(2023-24)-PL178-152-214

Page **25** of **28**



VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.



World's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelligentsystem.com

	in any way from fraudulent acts, misrepresentations or willful default on part of the client or companies, their directors, employees or agents.
14.	This report is having limited scope as per its fields & format to provide only the general basic idea of the value of the property prevailing in the market based on the site inspection and documents/ data/ information provided by the client. The suggested indicative prospective estimated value should be considered only if transaction is happened as free market transaction.
15.	The sale of the subject property is assumed to be on an all cash basis. Financial arrangements would affect the price at which the property may sell for if placed on the market.
16.	The actual realizable value that is likely to be fetched upon sale of the asset under consideration shall entirely depend on the demand and supply of the same in the market at the time of sale.
17.	While our work has involved an analysis & computation of valuation, it does not include detailed estimation, design/technical/ engineering/ financial/ structural/ environmental/ architectural/ compliance survey/ safety audit & works in accordance with generally accepted standards of audit & other such works. The report in this work in not investigative in nature. It is mere an opinion on the likely estimated valuation based on the facts & details presented to us by the client and third party market information came in front of us within the limited time of this assignment, which may vary from situation to situation.
18.	Where a sketched plan is attached to this report, it does not purport to represent accurate architectural plans. Sketch plans and photographs are provided as general illustrations only.
19.	Documents, information, data including title deeds provided to us during the course of this assessment by the client is reviewed only upto the extent required in relation to the scope of the work. No document has been reviewed beyond the scope of the work. These are not reviewed in terms of legal rights for which we do not have expertise. Wherever any information mentioned in this report is mentioned from the documents like owners name, etc., it is only for illustration purpose and may not necessary represent accuracy.
20.	The report assumes that the borrower/company/business/asset complies fully with relevant laws and regulations applicable in its area of operations and usage unless otherwise stated, and that the companies/business/assets is managed in a competent and responsible manner. Further, as specifically stated to the contrary, this report has given no consideration to matters of a legal nature, including issues of legal title and compliance with relevant laws, and litigations and other contingent liabilities that are not recorded/reflected in the documents/ details/ information/ data provided to us.
21.	This valuation report is not a qualification for accuracy of land boundaries, schedule (in physical terms), dimensions & identification. For this land/ property survey report can be sought from a qualified private or Govt. surveyor.
22.	This Valuation report is prepared based on the facts of the property on the date of the survey. Due to possible changes in market forces, socio-economic conditions, property conditions and circumstances, this valuation report can only be regarded as relevant as at the valuation date. Hence before financing, Banker/ FI should take into consideration all such future risk and should loan conservatively to keep the advanced money safe in case of the downward trend of the property value.
23.	Valuation of the same asset/ property can fetch different values under different circumstances & situations. For eg. Valuation of a running/ operational shop/ hotel/ factory will fetch better value and in case of closed shop/ hotel/ factory it will have considerable lower value. Similarly, an asset sold directly by an owner in the open market through free market transaction then it will fetch better value and if the same asset/ property is sold by any financer due to encumbrance on it, will fetch lower value. Hence before financing, Lender/ FI should take into consideration all such future risks while financing and take decision accordingly.
24.	Valuation is done for the property identified to us by the owner/ owner representative. At our end we have just visually matched the land boundaries, schedule (in physical terms) & dimensions of the property with reference to the documents produced for perusal. Method by which identification of the property is carried out is also mentioned in the report clearly. Responsibility of identifying the correct property to the Valuer/ its authorized surveyor is solely of the client/ owner for which Valuation has to be carried out. It is requested from the Bank to cross check from their own records/ information if this is the same property for which Valuation has to be carried out to ensure that owner has not misled the Valuer company or misrepresented the property due to any vested interest. Where there is a doubt about the precision position of the boundaries, schedule, dimensions of site & structures, it is recommended that a Licensed Surveyor be contacted.
25.	In India more than 70% of the geographical area is lying under rural/ remote/ non municipal/ unplanned area where the subject property is surrounded by vacant lands having no physical demarcation or having any display of property survey or municipal number / name plate on the property clearly. Even in old locations of towns, small cities & districts where property number is either not assigned or not displayed on the properties clearly and also due to the presence of multiple/ parallel departments due to which ownership/ rights/ illegal possession/ encroachment issues are rampant across India and due to these limitations at many occasions it becomes tough to identify the property with 100% surety from the available documents, information & site whereabouts and thus chances of error, misrepresentation by the borrower and margin of chances of error always persists in such cases. To avoid any such chances of error it is advised to the Bank to engage municipal/ revenue department officials to get the confirmation of the property to ensure that the property shown to Valuer/ Banker is the same as for which documents are provided.
26.	If this Valuation Report is prepared for the Flat/ dwelling unit situated in a Group Housing Society or Integrated Township then approvals, maps of the complete group housing society/ township is out of scope of this report and

FILE NO.: VIS(2023-24)-PL178-152-214

Page **26** of **28**



Integrating Valuation Life Cycle

VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.

REINFORCING YOUR BUSINESS ASSOCIATES VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.

ALUATION CENTER OF EXCELLENCE

www.valuationintelligentsystem.com this report will be made for the specific unit based on the assumption that complete Group Housing Society/ Integrated Township and the subject unit must be approved in all respect. Due to fragmented & frequent change in building/ urban planning laws/ guidelines from time to time, different laws/ 27. guidelines between regions/ states and no strict enforceability of Building Bye-Laws in India specially in non-metro and scale b & c cities & Industrial areas, property owners many times extend or make changes in the covered area/ layout from the approved/ applicable limits. There are also situations where properties are decades old when there was no formal Building Bye-Laws applicable the time when the construction must have been done. Due to such discrete/ unplanned development in many regions sometimes it becomes tough for the Valuer to determine the exact lawful situation on ground. Unless otherwise mentioned in the report, the covered area present on the site as per site survey will be considered in the Valuation. Area of the large land parcels of more than 2500 sq.mtr or of uneven shape in which there can be practical difficulty in sample measurement, is taken as per property documents which has been relied upon unless otherwise stated. 29. Drawing Map, design & detailed estimation of the property/ building is out of scope of the Valuation services 30 Valuation is a subjective field and opinion may differ from consultant to consultant. To check the right opinion, it is important to evaluate the methodology adopted and various data point/ information/ factors/ assumption considered by the consultant which became the basis for the Valuation report before reaching to any conclusion. 31. Although every scientific method has been employed in systematically arriving at the value, there is, therefore, no indisputable single value and the estimate of the value is normally expressed as falling within a likely range. 32. Value analysis of any asset cannot be regarded as an exact science and the conclusions arrived at in many cases will, of necessity, be subjective and dependent on the exercise of individual judgment. Given the same set of facts and using the same assumptions, expert opinions may differ due to the number of separate judgment decisions, which have to be made. Therefore, there can be no standard formula to establish an indisputable exchange ratio. In the event of a transaction, the actual transaction value achieved may be higher or lower than our indicative analysis of value depending upon the circumstances of the transaction. The knowledge, negotiability and motivations of the buyers and sellers, demand & supply prevailing in the market and the applicability of a discount or premium for control will also affect actual price achieved. Accordingly, our indicative analysis of value will not necessarily be the price at which any agreement proceeds. The final transaction price is something on which the parties themselves have to agree. However, our Valuation analysis can definitely help the stakeholders to take informed and wise decision about the Value of the asset and can help in facilitating the arm's length transaction. This Valuation is conducted based on the macro analysis of the asset/ property considering it in totality and not based on the micro, component, or item wise analysis. Analysis done is a general assessment and is not investigative This report is prepared on the RKA V-L1 (Basic) Valuation format as per the client requirement and scope of work. 34. This report is having limited scope as per its fields & format to provide only the general estimated & indicative basic idea of the value of the property prevailing in the market based on the information provided by the client. No detailed analysis, audit or verification has been carried out of the subject property. There may be matters, other than those noted in this report, which might be relevant in the context of the transaction and which a wider scope might uncover. This is just an opinion report and doesn't hold any binding on anyone. It is requested from the concerned Client/ Bank/ Financial Institution which is using this report for mortgaging the property that they should consider all the different associated relevant & related factors & risks before taking any business decision based on the content of this report. All Pages of the report including annexures are signed and stamped from our office. In case any paper in the report 36. is without stamp & signature then this should not be considered a valid paper issued from this office. As per IBA Guidelines & Bank Policy, in case the valuation report submitted by the valuer is not in order, the banks 37. / FIs shall bring the same to the notice of the valuer within 15 days of submission for rectification and resubmission. In case no such communication is received, it shall be presumed that the valuation report has been accepted. 38. Defect Liability Period is 15 DAYS. We request the concerned authorized reader of this report to check the contents, data, information, and calculations in the report within this period and intimate us in writing at valuers@rkassociates.org within 15 days of report delivery, if any corrections are required or in case of any other concern with the contents or opinion mentioned in the report. If no intimation is received within 15 (Fifteen) days in

Valuation Services will be entertained due to possible change in situation and condition of the property. 39. Though adequate care has been taken while preparing this report as per its scope, but still we can't rule out typing, human errors, over sightedness of any information or any other mistakes. Therefore, the concerned organization is advised to satisfy themselves that the report is complete & satisfactory in all respect. Intimation regarding any discrepancy shall be brought into our notice immediately. If no intimation is received within 15 (Fifteen) days in writing from the date of issuance of the report, to rectify these timely, then it shall be considered that the report is complete in all respect and has been accepted by the client upto their satisfaction & use and further to which R.K. Associates shall not be held responsible in any manner.

writing from the date of issuance of the report, then it shall be considered that the report is complete in all respect and has been accepted by the client upto their satisfaction & use and further to which R.K Associates shall not be held responsible in any manner. After this period no concern/ complaint/ proceedings in connection with the

40. Our Data retention policy is of ONE YEAR. After this period we remove all the concerned records related to the assignment from our repository. No clarification or query can be answered after this period due to unavailability of the data.

FILE NO.: VIS(2023-24)-PL178-152-214

Page **27** of **28**



VALUATION ASSESSMENT M/S. MEDISYS BIOTECH PVT. LTD.

REINFORCING YOUR BUSINESS®

ASSOCIATES

VALUERS & TECHNO ENGINEERING CONSULTANTS (P) LTD.

ING CONSULTANTS (P) LTD.

VALUATION CENTER OF EXCELLENCE

Vorld's first fully digital Automated Platform for Integrating Valuation Life Cycle -A product of R.K. Associates www.valuationintelliaentsystem.com

41.	This Valuation report is governed by our (1) Internal Policies, Processes & Standard Operating Procedures, (2) R.K.
	Associates Quality Policy, (3) Valuation & Survey Best Practices Guidelines formulated by management of R.K.
	Associates, (4) Information input given to us by the customer and (4) Information/ Data/ Facts given to us by our
	field/ office technical team. Management of R.K Associates never gives acceptance to any unethical or
	unprofessional practice which may affect fair, correct & impartial assessment and which is against any prevailing
	law. In case of any indication of any negligence, default, incorrect, misleading, misrepresentation or distortion of
	facts in the report then we request the user of this report to immediately or atleast within the defect liability period to
	bring all such act into notice of R.K Associates management so that corrective measures can be taken instantly.

42. R.K Associates never releases any report doing alterations or modifications by pen. In case any information/ figure of this report is found altered with pen then this report will automatically become null & void.

43. We are fully aware that based on the opinion of value expressed in this report, we may be required to give testimony or attend court / judicial proceedings with regard to the subject assets, although it is out of scope of the assignment, unless specific arrangements to do so have been made in advance, or as otherwise required by law. In such event, the party seeking our evidence in the proceedings shall bear the cost/professional fee of attending court / judicial proceedings and my / our tendering evidence before such authority shall be under the applicable laws.

44. The final copy of the report shall be considered valid only if it is in hard copy on the company's original letter head with proper stamp and sign on it of the authorized official upon payment of the agreed fees. User shall not use the content of the report for the purpose it is prepared for only on draft report, scanned copy, email copy of the report and without payment of the agreed fees. In such a case the report shall be considered as unauthorized and misused.



